Compare SGRY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | SUPN |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2015 | 2014 |
| Metric | SGRY | SUPN |
|---|---|---|
| Price | $26.81 | $29.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $24.40 | ★ $54.14 |
| AVG Volume (30 Days) | ★ 7.0M | 2.4M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.14 | ★ 8100.00 |
| EPS | N/A | ★ 2.78 |
| Revenue | $1,145,438,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | $51.56 |
| Revenue Next Year | N/A | $30.35 |
| P/E Ratio | ★ N/A | $10.65 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $11.41 | $25.92 |
| 52 Week High | $27.23 | $59.68 |
| Indicator | SGRY | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 89.82 | 31.65 |
| Support Level | $13.25 | $25.92 |
| Resistance Level | N/A | $51.59 |
| Average True Range (ATR) | 0.28 | 2.00 |
| MACD | 0.31 | -0.52 |
| Stochastic Oscillator | 90.62 | 19.96 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.